Allegion stock reports 12.7 percent Q2 revenue growth
π Allegion reported Q2 revenue of $1.15 billion, marking a 12.7% year-over-year increase driven by strong Americas demand.
π° Adjusted EPS reached $2.40, beating the consensus estimate of $2.22 and reflecting 17.6% growth compared to the prior year.
π Americas organic revenue grew 8.9% due to robust activity in education, healthcare, government, hospitality, and retail sectors.
π International organic revenue contracted 1.2% despite a reported segment increase of 16.2%, highlighting regional operational challenges.
π’ Acquisitions contributed 5.1% to total company sales, supporting overall top-line growth alongside organic expansion.
π― Management guided fiscal 2026 adjusted EPS between $8.85 and $9.00, providing a clear outlook for future performance.
π Nine brokerages maintain a Hold consensus with an average price target of $162.50, implying modest upside potential.
πΉ The stock trades at $154.21 with a market cap of $13.1 billion, sitting within its 52-week range of $125 to $183.
- Allegion delivered Q2 revenue of $1.15 billion, up 12.7% year over year, demonstrating strong top-line momentum.
- Adjusted EPS of $2.40 exceeded analyst expectations of $2.22, showcasing the company's ability to beat consensus estimates.
- Americas organic revenue grew 8.9%, driven by diverse demand across education, healthcare, government, and retail sectors.
- Acquisitions added 5.1% to sales, indicating a successful strategy of expanding market presence through M&A.
- Management provided clear fiscal 2026 guidance for adjusted EPS between $8.85 and $9.00, signaling confidence in future earnings.
- International organic revenue fell 1.2% year over year, indicating weakness outside the Americas region.
- European demand remains a counter-factor to overall growth, creating a geographic imbalance in performance.
- Enterprise resource planning disruption is cited as a material issue affecting international operations and segment results.